0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > TIGIT > TIT-H82E6

Biotinylated Human TIGIT Protein, His,Avitag™ (MALS verified)

  • Synonym
    TIGIT,VSIG9,VSTM3
  • Source
    Biotinylated Human TIGIT, His,Avitag (TIT-H82E6) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).
    Predicted N-terminus: Met 22
  • Molecular Characterization
    Online(Met 22 - Pro 141) Q495A1-1

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.

    The protein has a calculated MW of 30.5 kDa. The protein migrates as 33-40 kDa and 42-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Application
    TIT-H82E6 works best for experiments that test the binding between TIGIT and candidate antibodies, such as biopanning and other relevant assays.
    This product is NOT suitable for testing TIGIT-CD155 binding. For this type of application, we strongly recommend you to choose TIT-H82F1 as an alternative.
  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human TIGIT, His,Avitag (Cat. No. TIT-H82E6) SDS-PAGE gel

Biotinylated Human TIGIT, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS
Biotinylated Human TIGIT, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human TIGIT, His,Avitag (Cat. No. TIT-H82E6) was more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human TIGIT, His,AvitagBiotinylated Human TIGIT, His,Avitag (Cat. No. TIT-H82E6) ELISA bioactivity

Immobilized Human TIGIT Antibody at 2 μg/mL (100 μL/well) can bind Biotinylated Human TIGIT, His,Avitag (Cat. No. TIT-H82E6) with a linear range of 0.4-3 ng/mL (QC tested).

  • Background
    T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
  • References
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $1380.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:8 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop